Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAvMed 4-Tier Prescription Formulary Coverage | Ope…
    Ask Trek AI about this page
    CurrentAvMedPolicy N/A

    AvMed Employer Plans 4-Tier Prescription Drug Formulary

    Customize your policy alerts

    Sign up for all AvMed policy alerts

    Know when AvMed releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Rules and guidance for prescription drug coverage, formulary tiers, pharmacy use, prior authorization, and related pharmacy benefit processes for AvMed employer plan members.

    Policy Summary
    PayerAvMed
    PolicyEmployer Plans 4-Tier Prescription Drug Formulary
    Policy CodePolicy N/A
    Change TypeNo material change (routine revision)
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests with supporting clinical documentation via fax or the AvMed website; urgent decisions in 24 hours, standard in 1–3 business days.
    SourceLink
    4formulary tiers
    90-daymax mail supply
    30-90 dayssupply durations
    fax & webprior auth methods
    multiplePA / QL prevalence

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    partialdocument segment

    Coverage Criteria and Formulary Entries

    General coverage criteria and limitations

    General coverage stance, limitations, and common exclusions.

    Formulary is a reference guide and does not guarantee or define benefit coverage; member-specific benefits may vary and members should consult Member Engagement for coverage questions.
    AvMed may change coverage criteria and formulary placement over time based on new medication approvals, availability of generics, clinical data, or safety concerns.
    Supply limits: retail prescriptions covered up to a 90-day supply (refill generally after 75% used); mail-service covers 31–90 day supply and mail copay applies even if supply < 90 days; specialty drugs limited to a 30-day supply and dispensed through Plan Specialty Pharmacy unless manufacturer packaging dictates otherwise.
    Non-covered / commonly excluded items include OTC medications (unless specified), experimental or non‑FDA medications, replacement drugs for lost/stolen prescriptions (unless specified by the member's plan), fertility agents (unless covered by the member's plan), treatments for sexual dysfunction (unless specified), vitamins/minerals, nutritional supplements/medical foods, cosmetic products, weight-loss products (unless specified), compounded prescriptions except pediatric preparations, and pharmaceuticals covered under the medical benefit (e.g., immunizations, supplies, physician‑administered medications).
    Requests for non‑formulary coverage or exceptions require medical record documentation supporting medical necessity, contraindication to all formulary alternatives, or therapeutic failure of adequate trials as described in the member's benefit; quantity limit exceptions require a prescriber statement of medical necessity via the prior authorization process.
    Clinically Equivalent Drugs (CED) require prescriber-submitted clinical documentation and are subject to prior authorization and the CED policy path.

    COVERAGE CRITERIA — Tier structure and member cost-sharing guidance

    Tier structure and member cost-sharing guidance.

    Formulary uses a 4-tier structure: Tier 1 = Preferred Generic; Tier 2 = Preferred Brand & Other Generic; Tier 3 = Non‑Preferred Brand; Tier 4 = Specialty drugs. ACA‑designated preventive drugs may be $0 copay per benefit documents.
    Members should consult their specific plan documents for copay, coinsurance, and deductible details. Choosing lower‑tier (Tier 1 or 2) medications generally reduces out‑of‑pocket costs; providers/patients should consider therapeutic alternatives on lower tiers when clinically appropriate.
    Specialty drugs (Tier 4) typically have unique handling (limited to 30‑day supply, often dispensed via specialty pharmacy) and may carry specialty cost‑sharing and utilization controls.

    Selected formulary coverage entries (anti-infectives/antivirals)

    Formulary entries list drug name, Drug Tier, and Requirements / Limits where applicable. Examples from the provided section include:

    fluconazole oral tablet 100 mg, 200 mg — Tier 1; Requirements / Limits = QL (4 per 1 day).
    CRESEMBA oral capsule 186 mg — Tier 3; Requirements / Limits = PA; QL (2 per 1 day).
    ORAVIG — Tier = CED; Requirements / Limits = PA; 14 tablets per fill.
    posaconazole oral suspension — Tier 2; Requirements / Limits = PA; QL (20 per 1 day).
    BIKTARVY — Tier 4; Requirements / Limits = SP (specialty).
    PAXLOVID dose pack 150 mg — Tier 2; Requirements / Limits = QL (40 per 365 days).

    Sample drug coverage entries (from excerpt)

    Drug-specific coverage tier and requirement/limits entries as listed in the formulary excerpt.

    VALCYTE oral reconstituted solution — Tier 4; Requirements / Limits = PA for age 9 and older; SP.
    VIREAD oral powder — Tier = CED; Requirements / Limits = PA; SP; QL (8 per 1 day).
    XOFLUZA oral tablet — Tier 3; Requirements / Limits = QL (1 per 183 days).
    DIFICID oral tablet — Tier 3; Requirements / Limits = PA; 20 tablets per fill.
    Class examples: Various penicillins and cephalosporins — tiers vary (Tier 1–3); most have no limits but some specific products listed as Tier 3.
    ARIKAYCE — Tier 4; Requirements / Limits = PA; SP; LA; QL (8.4 per 1 day).

    Selected drug criteria from this section

    Drug-specific coverage tier and applicable requirements/limits

    abiraterone oral tablet 250 mg — Tier 4; Requirements / Limits = PA; SP; QL (4 per 1 day).
    SEYSARA — Tier 3; Requirements / Limits = ST (step therapy).
    BLUJEPA — Tier 3; Requirements / Limits = PA; QL (20 per 30 days).
    COMETRIQ oral capsule 100 mg/day — Tier 4; Requirements / Limits = PA; SP; QL (56 per 28 days).
    ELIGARD (3‑month) — Tier 4; Requirements / Limits = PA; SP; QL (1 per 63 days).

    Adjunctive agents coverage entries (sample nodes)

    This segment lists individual drugs with their assigned drug tier and any specific requirements or limits for coverage.

    LIFYORLI oral capsule 125 mg/day — Tier 4; Requirements / Limits = PA; SP; QL (18–27 per 28 days depending on strength).
    LONSURF oral tablet 15–6.14 mg — Tier 4; Requirements / Limits = PA; SP; QL (6–8 per 1 day depending on formulation).
    Leuprolide subcutaneous kit — Tier 4; Requirements / Limits = PA; SP; QL (2 per 28 days).
    Sample note: Multiple entries in this segment are marked CED or LA and have PA, SP, and QL as noted per product; quantity limits vary by drug.

    Coverage with utilization controls

    Coverage stance is tiered; many medications are covered with conditions (prior authorization, step therapy, quantity limits) or are assigned to a Coverage with Evidence Development (CED) status for certain formulations.

    Each drug line is assigned a formulary tier (Tier 1–4 or CED) and may include requirement flags such as PA, SP, ST, LA, CED, or QL next to the drug name.
    Common utilization controls include: Prior Authorization (PA), Step Therapy / Supported Trial (ST), Specialty dispensing (SP), Limited Access or site/provider restrictions (LA), and Quantity Limits (QL) with explicit numeric limits (per day, per 28/30/63/365 days).
    CED examples: Some agents/formulations are marked CED (coverage contingent on evidence or criteria); other high‑cost agents show PA; SP; LA designations (examples include TROKENDI XR = CED with PA; EPIDIOLEX = PA; SP; LA).

    Adjunctive agents: tier and utilization controls

    Per-drug formulary entries include a tier and any of: PA, QL, SP, LA, ST, CED. Quantity limits are specified in many entries with units (per day, per 28 days, per 30 days, per 365 days).

    Formulary lines consistently present: Drug name / Drug Tier / Requirements & Limits (examples of flags: PA, SP, QL, ST, LA, CED).
    Quantity limits appear in many formats (e.g., 'QL (1 per 1 day)', 'QL (32 per 28 days)', 'QL (28 per 365 days)', 'QL (2800 per 28 days)') and are enforced as shown per product.
    Where PA is indicated, prior authorization is required before coverage is approved; some products also require specialty pharmacy dispensing or have limited access/site restrictions.

    Adjunctive agents coverage entries

    Formulary entries include drug tier assignments and coverage requirements or limits; common requirement flags include PA (prior authorization), QL (quantity limits), SP (specialty), CED, ACA, OTC.

    Many adjunctive agents are Tier 3 or Tier 4 and include utilization controls such as PA and QL; some entries provide detailed per‑strength QL and age‑based PA requirements.
    Examples: BELBUCA — Tier 3; Requirements = PA; QL (2 per 1 day). BRIXADI formulations — Tier 4; Requirements = PA; SP; QL (product‑specific per 28 day expressions).
    Several topical and oral analgesic entries show CED or PA with specific QL (e.g., diclofenac topical pump QL 224 per 30 days; other topical forms CED with PA).

    Coverage criteria from formulary listings

    Formulary entries specify drug tier and any requirements/limits; some entries require PA, have QL, or are age-restricted.

    Naloxone injection solution — Tier = CED; Requirements / Limits = PA; QL (4 per 1 day). Naloxone injection syringe — Tier = 1; no limits listed in extract.
    NARCAN nasal spray — Tier 3; Requirements / Limits = 2 sprays per fill (example fill/unit restriction).
    VIVITROL — Tier 4; Requirements / Limits = SP (specialty).
    Age‑based examples: Intramuscular antipsychotics (e.g., ABILIFY MAINTENA, INVEGA SUSTENNA) commonly have PA for patients age 17 and younger and specific QL expressed as doses per 28/63 days.
    Stimulant/ADHD agents often include age‑based PA (e.g., PA for age 19 and older for many formulations) and per‑day QL restrictions.

    Per-drug coverage nodes

    Per-entry coverage designations and restrictions:

    Examples of per‑drug rules: dextroamphetamine‑amphetamine tablets — Tier 1; Requirements = PA for age 19 and older; QL (2 per day).
    ERZOFRI intramuscular syringes — Tier 2; Requirements = PA for age 17 and younger; QL specified as fractional doses per 28 days depending on strength (e.g., 0.75 per 28 days, 0.5 per 28 days).
    Some entries are marked CED or SP in addition to PA and have QL expressed per day/period (e.g., certain ER formulations, extended‑release methylphenidate forms).

    Long-acting injectables criteria

    Long-acting injectable antipsychotics:

    INVEGA SUSTENNA intramuscular formulations — Tier 2; Requirements = PA for age 17 and younger; QL specified per presentation (examples: QL 1 per 28 days; QL 0.75 per 28 days depending on strength).
    INVEGA TRINZA intramuscular formulations — Tier 2; Requirements = PA for age 17 and younger; QL specified per presentation (e.g., QL 0.88 per 63 days to 1.75 per 63 days depending on strength).
    Long‑acting injectables generally carry PA with age‑based restrictions and quantity limits expressed as dosing intervals (per 28/63/135 days as applicable).

    Stimulant coverage criteria

    Stimulants and methylphenidate family:

    Methylphenidate and related stimulant products are assigned across tiers (including CED for some formulations) and frequently require PA for patients age 19 and older for extended‑release formulations.
    Quantity limits for stimulant products are commonly per‑day (e.g., QL 1 per day, QL 2 per day, or product‑specific counts) and some products list specific per‑day maximums by strength.
    Representative entries: ADDERALL products — Tier 3; Requirements = PA for age 19+ for many strengths; QL varies by strength (e.g., 2–3 per day). MYDAYIS — Tier 3; Requirements = PA; QL (1 per 1 day).

    Selected product coverage entries

    Coverage stance and limits shown per product/strength:

    PAXIL CR extended‑release formulations — Tier = CED; Requirements = PA; QL (1–2 per 1 day depending on strength).
    Perphenazine oral tablets — Tier 2; Requirements = PA for age 17 and younger; QL (example 2–4 per 1 day depending on strength).
    Quetiapine products — tiers vary by formulation/strength; many have PA for age 17 and younger and per‑day QL values by strength (examples listed in the formulary).

    Extracted coverage entries

    Sample coverage stances and criteria from the extract (not exhaustive):

    MAVENCLAD (tablet pack) — Tier 4; Requirements = PA; dosing limits expressed (e.g., 2 tablets per day; 40 tablets in 720 days); SP; LA.
    MAYZENT — Tier 4; Requirements = PA; SP; QL (example: 12 per 365 days for certain strengths).
    PLEGRIDY pen/injector — Tier 4; Requirements = ST; SP; QL (1 per 28 days or as noted for starter/maintenance presentations).
    PONVORY — Tier 4; Requirements = PA; SP; QL (1 per 1 day).
    Aliskiren — Tier 2; Requirements = PA; QL (1 per 1 day).

    Formulary tier and utilization management indicators

    Coverage is indicated by drug tier and requirements/limits fields on each drug line.

    Drug lines consistently show a tier assignment (Tier 1–4 or CED) plus any requirement/limit flags; where PA is listed coverage requires prior authorization before dispensation.
    Quantity limits are enforced per product as listed (examples include 'QL (2 per 1 day)', 'QL (168 per 365 days)', 'QL (59 per 365 days)').
    Specialty and administrative flags: Some products require specialty pharmacy (SP), have limited access (LA), are subject to step therapy (ST), or are designated CED/ACA; providers should follow the listed flags for utilization control processes.

    Coverage criteria and utilization controls

    Products are assigned coverage tiers and utilization controls. Specific coverage requires meeting listed requirements (PA, ST, SP) and adhering to quantity limits.

    NEXLIZET — Tier 3; Requirements = PA; QL (1 per 1 day).
    PRALUENT PEN — Tier 3; Requirements = PA; QL (2 per 28 days).
    REPATHA SURECLICK — Tier 2; Requirements = PA; QL (3 per 28 days).
    ENTRESTO — Tier 3; Requirements = QL (2 per 1 day) as listed.
    Operational rule: When PA is indicated, the payer requires prior authorization prior to coverage; quantity limits are enforced as shown per product and specialty handling applies where SP/LA flags are present.

    Per-drug coverage rules (table-driven)

    Coverage is drug-specific with tier assignment and utilization controls; many products are covered subject to PA, SP, ST, and/or QL.

    Formulary entries follow the table pattern: Drug name; Drug Tier (1–4 or CED); Requirements / Limits (PA, SP, ST, LA, QL) where applicable. Specific numeric QL values are shown on many lines (per day, per 28/30/63/365 day periods).
    Examples from the antipsoriatic section: ZORYVE topical cream/foam — Tier 3; Requirements = PA; QL (1 per 30 days). DUPIXENT pens/syringes — Tier 4; Requirements = PA; SP; QL (product‑specific per 28 days).
    Where product lines show CED, PA, or SP flags, providers must submit required clinical documentation via the prior authorization process to establish medical necessity for coverage or exception.

    Formulary Codes, Tiering, and Quantity Limits

    Formulary definitionsmixed
    Defines Brand and Generic medication terms as used in the formulary.
    Formulary tier codes and special indicatorsmixed
    1Preferred Generic Drugs (Tier 1)
    2Preferred Brand & Other Generic Drugs (Tier 2)
    3Non-Preferred Brand Drugs (Tier 3)
    4Specialty Drugs (Tier 4)
    9Affordable Care Act Drug (ACA) - $0 Copay
    Formulary tiers and special coverage codemixedCovered
    Tier 1Lower-tier drugs (generic or preferred)
    Tier 2Mid-tier drugs
    Tier 3Non-preferred or higher-cost drugs
    Tier 4Specialty/high-cost drugs
    CEDCoverage with evidence development
    Formulary requirement codes presentmixed
    PAPrior Authorization required
    SPSpecialty
    QLQuantity Limit (examples shown as counts per time period)
    LALimited Access
    STStep Therapy
    CEDCoverage with Evidence Development / conditional entry (as used in table)
    Drug tier classification observedmixed
    No codes listed
    Formulary tiers and CED indicatorsmixed
    Formulary tier assignment (1-4 or CED) provided for each drug; CED indicates coverage with clinical evidence development
    Drug-level coding absentmixed
    No billing or clinical codes (CPT/HCPCS/ICD-10/NDC) are provided in these chunks; entries are drug names with tier and utilization flags.
    Formulary tiers and requirement tagsmixed
    No codes listed
    Codes not listedNDC
    No explicit billing or NDC codes provided in this segment.
    Formulary entries (no NDC/CPT codes present)mixed
    This document lists drug names, tiers, and requirement/limit codes (PA, QL, ST, SP, CED) but does not provide standardized billing or NDC codes in these chunks.
    Formulary tier indicatorsmixed
    Formulary tiers are indicated numerically (1-4) and with CED for certain products; no external code systems (NDC/CPT) provided in this excerpt.
    Formulary tieringmixed
    Drug tier assignments (1-4 and CED) are provided for listed products; no external coding (NDC/CPT/ICD-10) present in this extract.
    Formulary tiers / product strengthsmixed
    Formulary tier assignments (Tier 1-4, CED) and specific product strength listings; no clinical/ICD or CPT codes provided in this excerpt.
    Formulary tiers and requirement flagsmixed
    Formulary tier assignments (1-4, CED) and requirements/limits per product; no billing/CPT/ICD codes provided in excerpt.
    Formulary tiers and CED designationsmixed
    Formulary tier assignments (1-4 and CED) for listed drugs
    inv-34: Quantity limits — summary statement and exceptions
    Quantity limits — definitionMaximum quantity per prescription and/or time period for one copay or coinsurance (determined from FDA labeling and clinical guidelines).
    Exception processIf a prescription exceeds the quantity limit, prescriber must submit a statement of medical necessity and request a prior authorization for a quantity limit exception.
    Documentation requiredQuantity limit exceptions require medical necessity documentation submitted via the prior authorization process (fax or web).

    Authorization, Documentation, and Submission Requirements

    Prior Authorization

    Submit drug authorization form and clinical documentation

    Providers must submit a completed drug authorization request form plus supporting clinical documentation (e.g., lab values, prescription history, statement of medical necessity) via fax to 1305-671-0200 or through the AvMed website to obtain prior authorization. Decisions are generally returned within 24 hours for urgent requests and within 1–3 business days for standard requests.

    • Submit completed drug authorization request form and supporting clinical documentation
    • Include lab values, prescription history, statement of medical necessity or other pertinent information
    • Fax to 1305-671-0200 or submit via AvMed website
    Prior Authorization

    Request QL exception with medical necessity statement

    If a prescription exceeds a listed quantity limit, the prescriber must provide a statement of medical necessity and request a quantity limit exception through the prior authorization process.

    Definitions and Abbreviations

    inv-77: Brand Medication definition
    Brand Medication — definitionA prescription medication manufactured and sold under a name or trademark, or identified as a Brand by AvMed's PBM.
    Brand Additional Charge — definitionAn additional charge paid when a brand medication is chosen instead of an available generic; equals the cost difference and is paid in addition to the applicable copayment.
    Formulary Drug List — definitionA multitiered listing of preferred medications based on clinical efficacy, safety, and cost used to establish copayment levels.
    inv-78: Generic Medication definition
    Generic Medication — definitionA prescription medication with the same active ingredient as a brand medication or identified as generic by AvMed's PBM; FDA-approved generics are considered as effective and safe as brand-name products.
    Equivalence statement
    Policy Summary
    PayerAvMed
    PolicyEmployer Plans 4-Tier Prescription Drug Formulary
    Policy CodePolicy N/A
    Change TypeNo material change (routine revision)
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests with supporting clinical documentation via fax or the AvMed website; urgent decisions in 24 hours, standard in 1–3 business days.
    SourceLink
    On This Page
    Coverage Criteria and Formulary EntriesFormulary Codes, Tiering, and Quantity LimitsAuthorization, Documentation, and Submission RequirementsDefinitions and Abbreviations
    PAXLOVID dose pack 300 mg (150 mg x2) — Tier 2; Requirements / Limits = QL (60 per 365 days).
    EPCLUSA — Tier 4; Requirements / Limits = PA; SP; QL (1 per 1 day).
    PREVYMIS (tablets/pellets) — Tier 4; Requirements / Limits = PA; SP; QL (1–2 per 1 day depending on presentation).
    TEMBEXA oral suspension — Tier 3; Requirements / Limits = 65 mL per fill (example quantity limit).
    TOBI PODHALER — Tier 4; Requirements / Limits = ST; SP; QL (224 per 28 days).
    SOLOSEC — Tier = CED; Requirements / Limits = SP; PA; QL (1 per 30 days).
    Specialty supply noteSpecialty medications are limited to a 30-day supply; QL still applies and specialty dispensing rules may restrict quantity or site of fill.
    inv-35: Quantity limit examples
    Example: Paxlovid (dose pack 150 mg x2)QL (60 per 365 days)
    Example: Paxlovid (dose pack 150 mg x1)QL (40 per 365 days)
    General exampleQL values are often expressed as 'X per Y days' (e.g., 40 per 365 days).
    inv-36: Quantity limits examples
    Valganciclovir oral recon solutionPA for age 9 and older; SP (Quantity limits applied per formulation)
    ArikaycePA; SP; LA; QL (8.4 per 1 day)
    Alinia oral suspensionPA; QL (180 per 1 day)
    inv-37: Quantity limits examples
    BETHKIS (nebulized)SP; QL (224 per 28 days)
    CAYSTONSP; LA; QL (3 per 1 day)
    COARTEM (example) — general QL formatQL examples shown in table (e.g., COARTEM QL 24 per 365 days)
    inv-38: Common quantity limits
    Depot/long-acting injectables (e.g., Lupron Depot)QL expressed as doses per 28/63/84/126 days (e.g., 1 per 28 days; 1 per 63 days)
    Eligard formulationsPA; SP; QL (1 per 63 days, 1 per 84 days, or 1 per 126 days depending on product)
    Common formats for long-acting injectablesQuantity limits frequently given as '1 per X days' for depot products.
    inv-39: Quantity limits examples
    Abiraterone oral tablet 250 mgPA; SP; QL (4 per 1 day)
    VISTOGARDSP; QL (20 per 30 days)
    AFINITORPA; SP; QL (1 per 1 day)
    inv-40: Quantity limit examples
    ELIGARD (3-month)PA; SP; QL (1 per 63 days)
    LUPRON DEPOT (various intervals)PA; SP; QL (1 per 28/63/84/126 days depending on formulation)
    Format noteDepot products use QL expressed as one dose per multi-week/month interval.
    inv-41: Example quantity limits
    TROKENDI XR 200 mg (CED)PA; QL (2 per 1 day)
    VALTOCOPA; QL (10 per 30 days)
    XCOPRI (various strengths)PA; QL (1-2 per 1 day or 1 unit per day; some packs limited to 1 box per 365 days)
    inv-42: Quantity limits examples
    DUOPAPA; SP; QL (2800 per 28 days)
    INBRIJA inhalation capsulePA; SP; QL (10 per 1 day)
    Dihydroergotamine injections/nasalPA; QL (24 per 28 days for injection; 8 per 28 days for nasal)
    inv-43: Example quantity limits
    BELBUCAPA; QL (2 per 1 day)
    BRIXADI (various extended-release syringes)PA; SP; QL (examples: 0.36 per 28 days; 1.28 per 28 days; 1.92 per 28 days)
    Format — fractional QL for injectables/extended-releaseSome parenteral or extended-release products are expressed as fractional units per time period (e.g., 0.36 per 28 days).
    inv-44: Quantity limits examples
    ERZOFRI intramuscular syringesPA for age 17 and younger; QL examples include 0.75 per 28 days and 1 per 28 days depending on strength
    ERZOFRI 351 mgPA for age 17 and younger; QL (2.25 per 365 days)
    Age-based QL/PA interplaySome injectables combine age-based PA requirements with product-specific QL expressed per days or per year.
    inv-45: Quantity limits examples
    MAVENCLAD (8- or 9-tablet pack)PA; 2 tablets per day; 40 tablets in 720 days; SP; LA
    MAYZENT 0.25 mgPA; SP; QL (12 per 365 days)
    PLEGRIDY (pen/injector)ST; SP; QL (1 per 28 days or 1 per 365 days for certain packs)
    inv-46: Example quantity limits
    ORENITRAM titration kitsPA; SP; QL examples include 168 per 365 days up to 336 per 365 days depending on kit
    Eltrombopag formulationsPA; SP; QL (examples: 1 per 1 day; 3 per 1 day depending on strength)
    High annualized QL entriesSome products use QL expressed over 365 days (e.g., 168/365, 252/365, 336/365).
    inv-47: Common quantity limit formats
    Common QL formats — daily and multi-dayFormats shown include '1 per 1 day', '1 per 28 days', '0.5 per 63 days', '30 per 365 days'.
    Biologic/pen QL examplesBiologic autoinjectors often limited to '1 per 28 days' or '1 per 63 days' depending on product (e.g., COSENTYX, ILUMYA, DUPIXENT).
    Actionable referenceQuantity limits are consistently formatted as 'QL (X per Y days)' in the formulary; refer to product line for specific X/Y values.
    inv-48: Quantity limits examples
    DUPIXENT pen/syringePA; SP; QL (examples: 2.28 per 28 days; 4 per 28 days depending on presentation)
    VALCHLORPA; SP; QL (60 per 30 days)
    Typical topical QL formatsTopicals often use 'per 30 days' or 'per 365 days' (e.g., EFUDEX QL 40 per 365 days; ZORYVE QL 1 per 30 days)
  1. Provide a statement of medical necessity supporting the exception request
  2. Request the exception via the standard prior authorization submission channels
  3. Documentation Required

    Support non‑formulary requests with medical records and necessity

    Non‑formulary medication requests must be supported by medical record documentation showing a statement of medical necessity, contraindications to all formulary alternatives, or therapeutic failure of adequate trials (1–3 months) of each formulary alternative, submitted through the prior authorization process.

    • Include medical record documentation and/or prescription history
    • Document contraindications to ALL formulary alternatives or therapeutic failure after adequate trials (1–3 months)
    Prior Authorization

    Submit clinical documentation for CED medications

    Medications labeled CED require the prescriber to submit clinical documentation to establish medical necessity over comparable formulary alternatives and are subject to prior authorization.

    • Provide clinical justification that the CED medication is necessary over formulary alternatives
    • Submit documentation via the prior authorization process
    Prior Authorization

    Obtain PA before dispensing when indicated

    Prior authorization (PA) is required for certain drugs; the member or ordering prescriber must obtain approval from AvMed before the prescription will be covered.

    • Obtain PA approval prior to dispensing when ‘PA’ is indicated on the formulary
    • Use the AvMed drug authorization request form and submit required supporting documentation
    Step Therapy

    Follow step therapy trials or document reason to bypass

    Step therapy (ST) may require that specified drugs be tried first; if a required trial cannot be completed for clinical reasons, the prescriber may request prior authorization to bypass step requirements.

    • Attempt required first‑line agent(s) per ST before requesting alternative coverage
    • If trials cannot be completed, request PA and document medical reasons
    Billing Rule

    Adhere to listed quantity limits or request exception

    Quantity limits shown on formulary lines are enforced (examples include QL (1 per 1 day), QL (28 per 365 days), QL (6 per 28 days)); if prescribing beyond these limits, prescribers must request a PA/QL exception with supporting documentation.

    • Observe numeric QL formats (per day, per 28/30/365 days) listed per product
    • Request PA and provide medical necessity documentation to exceed QL
    Note

    Follow requirement flags shown on formulary lines

    Formulary entries include requirement flags such as PA, SP, QL, ST, LA, CED and ACA; when a flag appears next to a product the prescriber must follow the associated process (e.g., obtain PA when ‘PA’ is shown).

    • Check product line for requirement/limit codes before prescribing or dispensing
    • Follow indicated processes for PA, SP (specialty pharmacy), ST, LA, CED
    Prior Authorization

    Verify and act on authorization indicators in drug listings

    Drug listing rows include explicit authorization indicators (e.g., PA, SP, LA, ST, QL); prescribers should verify these indicators and submit prior authorization and supporting documentation when PA or specialty handling is required.

    • Verify Requirements / Limits codes on the formulary entry
    • Submit PA documentation when ‘PA’ is indicated and route specialty items per SP/LA instructions
    Prior Authorization

    Comply with PA, SP, and site limitations where shown

    Many drugs in the formulary segment require prior authorization, specialty pharmacy handling and/or quantity limits as specified per product; prescribers must obtain PA and comply with specialty/site restrictions where noted.

    • Obtain PA for products marked ‘PA’ before dispensing
    • Refer specialty items to participating specialty pharmacies when ‘SP’ or ‘LA’ is indicated
    Prior Authorization

    Meet utilization control requirements for coverage

    The formulary uses multiple utilization controls—PA, ST, SP, LA, CED and QL—for coverage decisions; prescribers must meet the listed requirements (e.g., trials, documentation, PA) to secure coverage.

    • Complete required step therapy trials when ST is indicated
    • Provide requested clinical documentation and obtain PA for coverage
    Prior Authorization

    Follow PA/SP/LA processes for products with specific controls

    Examples of specific controls appear on product lines (e.g., EPIDIOLEX: PA; SP; LA; FINTEPLA: PA; SP; LA; QL); when such controls are present the prescriber must follow PA and specialty procedures and supply supporting documentation.

    • Follow PA and specialty pharmacy routing for high‑cost agents listed with SP/LA
    • Provide required clinical documentation to support PA requests
    Documentation Required

    Confirm and satisfy utilization controls shown per product

    Prior authorization, step edits, quantity limits and other utilization controls are indicated next to many formulary drugs; prescribers should confirm the required edits on the product line and submit PA or documentation as applicable.

    • Confirm product‑specific ‘Requirements / Limits’ flags before prescribing
    • Submit PA and required clinical information when indicated
    Prior Authorization

    Obtain PA and follow quantity limits listed

    Formulary lines indicate when PA and quantity limits apply; prescribers must obtain PA and adhere to QL values noted for products (many adjunctive agents show PA and QL entries).

    • Obtain PA for products marked ‘PA’
    • Adhere to numeric QL entries (e.g., per day or per period) listed on the formulary
    Prior Authorization

    Check and document age‑based PA requirements

    Multiple products include age‑based prior authorization rules (for example, intramuscular antipsychotic injections such as INVEGA SUSTENNA require PA for age 17 and younger); prescribers must check age‑specific PA requirements and document accordingly.

    • Verify age‑based PA flags on product entries before prescribing for pediatric/adolescent patients
    • Include age and clinical justification in PA submission when required
    Billing Rule

    Adhere to per‑fill/unit restrictions or request exception

    Some products have special fill/unit restrictions (examples: NARCAN: 2 sprays per fill; OPVEE: 2 units per fill; ZIMHI: 1 ml per fill); prescribers and pharmacists must follow these per‑fill limits or request an exception via PA with justification.

    • Adhere to per‑fill unit limits noted on the formulary line
    • Request PA with medical necessity documentation to exceed per‑fill limits
    Prior Authorization

    Obtain PA for adjunctive agents with PA/QL flags

    The formulary repeatedly notes PA and quantity limits for many adjunctive agents; prescribers must obtain PA and provide required documentation for these listed products when coverage is conditioned on PA/QL.

    • Submit PA and supporting clinical information for adjunctive agents marked ‘PA’
    • Ensure QL values are observed or request an exception with justification
    Documentation Required

    Include age and dosing schedule for long‑acting injectables PA

    Several long‑acting injectable antipsychotics have age‑based PA (e.g., INVEGA TRINZA and INVEGA SUSTENNA require PA for age 17 and younger) and specific dose‑per‑period quantity limits; prescribers must include age and dosing schedule in PA submissions.

    • Include patient age and requested dosing interval in the PA documentation
    • Comply with the QL dosing schedule shown (dose per 28/63/135 days as applicable)
    Denial Risk

    PA required for many adjunctive agents — risk of denial if not obtained

    Prior authorization and quantity limits apply to many listed adjunctive agents (examples: PAXIL CR entries and perphenazine show PA and age‑specific limits); failure to obtain PA may result in non‑coverage or claim denial.

    • Obtain PA when PA is indicated on the formulary line
    • Document adherence to age‑ or strength‑specific limits to avoid denial
    Prior Authorization

    Route SP/LA products through specialty channels and obtain PA

    Some products are designated specialty (SP), limited access (LA), or require site/provider restrictions (e.g., sodium oxybate, SPRAVATO, WAKIX, XYREM/XYWAV); prescribers must route prescriptions to the appropriate specialty channel and obtain PA and site approvals when required.

    • Refer SP/LA items to participating specialty pharmacies per plan guidance
    • Obtain PA and comply with any site or provider limitations listed
    Step Therapy

    Document trials for step therapy or request PA to override

    Certain products have step therapy or supported trial requirements noted (for example, PLEGRIDY shows ST and many items are marked ST); prescribers must document completed trials or request PA to override step edits.

    • Document completed trials of required agents to satisfy ST
    • If unable to complete required trials, submit PA with clinical rationale to bypass ST
    Prior Authorization

    Review and comply with utilization controls to secure coverage

    Utilization controls (PA, ST, SP, CED, QL, LA) are present across the formulary and determine coverage; prescribers must meet the listed requirements and submit necessary documentation to obtain authorization and coverage.

    • Review the Requirements / Limits column for each product before prescribing
    • Provide required clinical documentation and obtain PA where indicated
    Billing Rule

    Follow the QL formats shown or request exception

    Quantity limit examples on the formulary include formats such as QL (1 per 1 day), QL (1 per 28 days), QL (30 per 365 days), and product‑specific numeric limits; prescribers must follow these QL formats or request an exception with medical necessity documentation.

    • Observe the QL timeframes and numeric limits specified per product
    • Submit PA and medical necessity documentation to exceed QLs
    Denial Risk

    Obtain PA and include required supporting info to avoid denials

    Many formulary drugs require PA and/or have quantity limits and specialty requirements; when PA is indicated prescribers must obtain authorization prior to dispensing and include requested supporting information to avoid denied claims.

    • Obtain PA prior to dispensing when ‘PA’ is listed
    • Include all requested supporting documentation (e.g., labs, prior therapy, medical necessity) in PA submission
    Prior Authorization

    Coordinate PA and specialty distribution for high‑cost items

    Several high‑cost specialty items require prior authorization plus specialty distribution and limits (examples: UPTRAVI, CABLIVI); prescribers should confirm SP/LA flags and coordinate specialty dispensing and PA requirements.

    • Confirm SP/LA designation on product entry and route to the designated specialty pharmacy
    • Obtain PA and comply with any specialty dosing or supply limits
    Note

    Follow PA/ST/QL/SP controls as summarized on formulary

    Summary: many drugs in this formulary require prior authorization, step therapy, and/or quantity limits; prescribers must follow the use‑case specific processes (PA submissions, clinical documentation, specialty routing) to obtain coverage.

    • Check each product’s Requirements / Limits before prescribing
    • Submit PA with clinical documentation and request QL or non‑formulary exceptions as needed
    Prior Authorization

    Utilization controls require compliance to secure coverage

    Overall utilization controls across the formulary require prescribers to obtain prior authorization, complete step therapy trials, or adhere to quantity limits and specialty routing as shown; failure to meet these controls can prevent coverage.

    • Meet PA, ST, QL, and SP requirements as listed per product
    • Document clinical rationale in the PA when requesting exceptions
    Note
    Generic medications contain identical active ingredients, same indications, and meet manufacturing standards equivalent to brand products.
    Formulary roleGenerics are typically placed on lower formulary tiers to reduce member cost-sharing.
    inv-79: Specialty Medication definition
    Specialty Medication — definitionA medication classified by AvMed as a specialty drug, generally for complex or ongoing conditions; must be prescribed by a provider and dispensed by a participating specialty pharmacy; limited to a 30-day supply.
    Dispensing requirementSome specialty drugs must be dispensed by a participating specialty pharmacy; limited availability (LA) flags may further restrict site of fill.
    Cost/tiering implicationSpecialty drugs are commonly assigned to Tier 4 (specialty/high-cost) and may require PA, SP, and QL controls.
    inv-80: Step Therapy definition
    Step Therapy — definitionA process requiring trial of one or more first- and/or second-line medications per AvMed guidelines before coverage of certain drugs will be approved; if trials cannot be completed for medical reasons, prescriber may request prior authorization.
    Operational noteST is indicated in the formulary by the 'ST' abbreviation next to products that require trials of preferred agents first.
    Appeal/exceptionIf trials are medically contraindicated or fail, prescriber should submit PA documentation to request coverage of the alternative drug.
    inv-81: Prior Authorization definition
    Prior Authorization — definitionProcess of obtaining approval for certain prescription drugs prior to dispensing according to AvMed guidelines; the ordering prescriber must obtain approval.
    Submission methodsPA requests may be submitted via fax (number provided in formulary) or through the AvMed website; decisions generally within 24 hours for urgent and 1-3 business days for standard requests.
    Required documentationPA requires completed drug authorization request form and supporting clinical documentation as specified in the formulary.
    inv-82: CED definition
    CED — definitionClinically Equivalent Drugs (CED) may not be covered if a clinically equivalent formulary drug is available; coverage may be contingent on documentation.
    Meaning of clinically equivalentA clinically equivalent drug is one that for most individuals will give similar results for a disease or condition.
    Action for members/providersContact Member Services for more information on CED listings and coverage criteria.
    inv-83: PA (abbreviation)
    PA — abbreviationPA = Prior Authorization — approval required before certain drugs are filled.
    Contextual usagePA appears next to products in the formulary to indicate prior authorization is required as a coverage condition.
    Related actionsWhen PA is indicated, prescriber must obtain approval or the drug may not be covered.
    inv-84: QL (abbreviation)
    QL — abbreviationQL = Quantity Limit — the amount of drug the Plan will cover for certain drugs (expressed as 'X per Y days').
    InterpretationQL entries in the formulary specify numeric limits and the time period (e.g., 'QL (4 per 1 day)', 'QL (30 per 365 days)').
    Exception routePrescribers may request a QL exception by submitting medical necessity documentation through the PA process.
    inv-85: SP (abbreviation)
    SP — abbreviationSP = Specialty (Specialty Pharmacy) designation.
    ImplicationSP indicates the drug is distributed through specialty channels and may require SP dispensing and associated PA or LA limitations.
    Typical tieringSP-designated drugs are commonly assigned to Tier 4 (specialty/high-cost).
    inv-86: ST (abbreviation)
    ST — abbreviationST = Step Therapy — requires trying specified drugs first before coverage for alternative drugs is approved.
    Operational noteST flags in the formulary indicate required trials; exceptions can be requested via PA with clinical justification.
    Relation to PAFailure or contraindication to required agents must be documented in a PA request to bypass ST requirements.
    inv-87: LA (abbreviation)
    LA — abbreviationLA = Limited Availability — prescription may be available only at certain pharmacies.
    Operational effectLA indicates site-of-fill restrictions; contact Customer Service for pharmacy locations or alternative arrangements.
    Common pairingLA often appears with SP or PA flags for high-cost or restricted products.
    inv-88: ACA (abbreviation)
    ACA — abbreviationACA = Affordable Care Act designation — certain preventive drugs may have $0 copay under ACA guidelines.
    ImplicationACA designation indicates a drug may be covered with zero member cost-sharing when it meets ACA preventive criteria.
    ReferenceRefer to member plan documents for ACA preventive drug lists and applicability.
    inv-89: Refer to the beginning of the table for definitions of symbols and abbreviations
    Refer to table header for symbolsThe document instructs readers to refer to the beginning of the formulary table for definitions of symbols and abbreviations used (e.g., PA, SP, QL).
    Why it mattersAbbreviations shown in this extract are defined in the full table header; consult the table header for authoritative symbol meanings.
    Contact for clarificationContact Member Services or review the full formulary table header for any unclear abbreviation meanings.
    inv-90: Prior Authorization (PA) short-form
    PA (short-form) — core meaningPA = Prior Authorization; approval required before certain drugs are covered.
    Use in tablePA appears next to drugs that require prescriber approval before dispensing; lack of PA may result in non-coverage.
    How to submitPA requests are submitted per the Prior Authorization Process (fax or web) described in the formulary.
    inv-91: Quantity Limit (QL) short-form
    QL (short-form) — core meaningQL = Quantity Limit — the Plan's limit on the amount it will cover for a drug per prescription/time period, shown as 'X per Y days'.
    Examples in tableMultiple QL examples appear in the formulary (e.g., '1 per 1 day', '28 per 365 days', '224 per 28 days').
    Exception routePrescriber may request a QL exception via PA with medical necessity justification.
    inv-92: Specialty (SP) short-form
    SP (short-form) — core meaningSP = Specialty Pharmacy / Specialty designation — indicates specialty handling or dispensing requirements for the drug.
    Relation to tiersSP items are commonly Tier 4 specialty drugs and may require PA and limited supply durations (30 days).
    Distribution noteSP may require dispensing through a participating specialty pharmacy and additional program requirements.
    inv-93: CED (table designation shown)
    CED (table designation shown)CED = Clinically Equivalent Drugs — may not be covered if a clinically equivalent formulary drug exists; refer to table header for full details.
    Implication for coverageCED indicates coverage contingent on criteria or evidence development; consult Member Services for specifics.
    inv-94: Table abbreviations reference
    Table abbreviations — referenceThe formulary uses abbreviations (PA, QL, SP, ST, LA, CED, ACA) defined at the beginning of the full table; refer to the table header for authoritative meanings.
    Legend locationThe table legend and abbreviation definitions are located at the start of the full formulary table (not always repeated in excerpts).
    Action if unclearIf abbreviations are unclear in an excerpt, consult the full formulary PDF or contact Member Services.
    inv-95: Table abbreviations reference (legend at table start)
    Table legend referenced — symbols/abbreviationsSymbols and abbreviations used in the table (e.g., PA, SP, QL, LA, CED) are defined at the beginning of the full formulary table.
    Excerpt limitationThis extract repeatedly refers readers to the table header for full definitions that are not included in the excerpt.
    RecommendationReview the primary table header in the full formulary for any formal definitions before applying codes operationally.
    inv-96: PA short-form reference
    PA — short-form referencePA indicates Prior Authorization is required before the Plan will cover the drug.
    Operational detailPrescribers must obtain PA per the Prior Authorization Process guidelines to avoid non-coverage.
    inv-97: QL short-form reference
    QL — short-form referenceQL indicates a Quantity Limit formatted as 'X per Y days' that restricts how much the plan will cover.
    ExamplesExamples in the formulary include 'QL (1 per 1 day)', 'QL (28 per 365 days)', 'QL (224 per 28 days)'.
    inv-98: Specialty Pharmacy (SP) short-form reference
    SP — Specialty Pharmacy short-form referenceSP marks drugs that require specialty pharmacy handling or designation.
    ImplicationSP drugs often require PA and may be restricted to specialty distribution channels.
    inv-99: Limited Access (LA) short-form reference
    LA — Limited Access short-form referenceLA indicates limited availability or site-of-fill restrictions for the medication.
    Operational effectLA may restrict dispensing to certain pharmacies or require additional coordination with the Plan.
    inv-100: Step Therapy (ST) short-form reference
    ST — Step Therapy short-form referenceST denotes Step Therapy — required trial of specified drugs prior to coverage of alternatives; exceptions via PA possible.
    Table usageST appears next to products that have step edit requirements in the formulary listing.
    inv-101: Coverage/Clinical Evidence Dependent (CED) short-form reference
    CED — Coverage/Clinical Evidence Dependent short-formCED indicates coverage may be conditional or require evidence development; may limit coverage if clinically equivalent formulary drug exists.
    Operational noteCED entries typically require additional clinical documentation or meet specific coverage criteria.
    inv-102: Table symbols/abbreviations — legend referenced
    Table legend — symbols/abbreviationsThe formulary's table legend defines symbols and abbreviations used throughout the drug listing; users should consult the table start for definitions.
    Why consult legendExcerpts omit the full legend; the header provides the authoritative mapping (e.g., PA, QL, SP, ST, LA, CED, ACA).
    inv-103: PA short-form reference (later segment)
    PA — reference (later segment)PA indicates Prior Authorization; follow the Prior Authorization Process for submission and required documentation.
    QL exception routeIf quantity exceeds limit, submit medical necessity statement with PA request as described in the Quantity Limit Exception section.
    inv-104: QL short-form reference (later segment)
    QL — reference (later segment)QL denotes Quantity Limit; exceptions require a PA with supporting medical necessity documentation.
    Example formattingShown in formulary as 'QL (X per Y days)' (e.g., 4 per 1 day; 30 per 365 days).
    inv-105: Table abbreviations/symbols referenced
    Abbreviations referenced in tableCommon formulary abbreviations include PA, QL, SP, ST, LA, CED, ACA; meanings available in the table header.
    Use instructionRefer to the beginning of the full formulary table for authoritative definitions prior to applying requirements operationally.
    inv-106: Formulary abbreviations explained
    Formulary abbreviations explained — summaryPA = Prior Authorization; QL = Quantity Limit; ST = Step Therapy; SP = Specialty; CED = Clinically Equivalent Drugs; LA = Limited Availability; ACA = Affordable Care Act.
    Legend locationDefinitions are provided at the beginning of the formulary table; consult that section for full descriptions.
    inv-107: Formulary abbreviations (legend referenced)
    Formulary legend — noteThe document repeatedly instructs readers to consult the table header for full definitions of abbreviations and symbols used in the listings.
    Implication for excerptsExcerpts may omit the complete legend; always cross-check with the full formulary table header.
    inv-108: Table symbols and abbreviations reference
    PA — short reference in listingsPA appears next to products requiring prior authorization; follow submitted PA procedures for coverage.
    Submission channelsPA submissions accepted via fax or AvMed website; urgent requests handled within 24 hours and standard in 1–3 business days.
    inv-109: Symbols and abbreviations — refer to table header
    QL — short reference in listingsQL appears next to products to limit covered quantity per time period; exceptions require PA with medical necessity documentation.
    Common expressionsExpressed as 'QL (X per Y days)' across the formulary entries.
    inv-110: Table abbreviations list
    Common table abbreviations — listPA, SP, QL, LA, ST, CED, ACA are used in the formulary; their meanings are defined in the table header.
    Where to find definitionsDefinitions are located at the beginning of the full formulary table; consult that legend for exact meanings.
    inv-111: Formulary abbreviations (as used in table)
    Formulary abbreviations — concise referencePA = Prior Authorization; SP = Specialty Pharmacy; QL = Quantity Limit; ST = Step Therapy; CED = Clinically Equivalent Drug; LA = Limited Availability; ACA = Affordable Care Act designation.
    Practical useThese abbreviations annotate requirements/limits on each drug line in the formulary; consult header for details.